WO1997000082A1 - Novel use of collagenase - Google Patents

Novel use of collagenase Download PDF

Info

Publication number
WO1997000082A1
WO1997000082A1 PCT/EP1996/002480 EP9602480W WO9700082A1 WO 1997000082 A1 WO1997000082 A1 WO 1997000082A1 EP 9602480 W EP9602480 W EP 9602480W WO 9700082 A1 WO9700082 A1 WO 9700082A1
Authority
WO
WIPO (PCT)
Prior art keywords
collagenase
treatment
novel use
preparation
wounds
Prior art date
Application number
PCT/EP1996/002480
Other languages
German (de)
French (fr)
Inventor
Josef Johna
Lothar Rasthofer
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of WO1997000082A1 publication Critical patent/WO1997000082A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase

Definitions

  • the present invention relates to a new application of collagenase in veterinary medicine.
  • wounds caused by abrasions or infections are treated with main care products or with germicidal substances (antibiotics).
  • antibiotics germicidal substances
  • Such wounds are partly treated with oils, covering the damaged area of the skin with the oil or an oil-containing product and protecting it from external influences. This does not accelerate the actual healing process. Treatment with antibiotic-containing products is also quite lengthy and in many cases unsuccessful.
  • the invention relates to the use of collagenase for the production of externally applicable medicaments for the treatment of wounds on large animals carrying files.
  • a suitable collagenase is, for example, that which is obtained from Clostridia histolyticum and is also used in human medicine. However, it can also be isolated from other Clostridia bacteria or tissues (Merck Index, No. 2477).
  • the mixtures usually used for skin care can be used as the basis for the preparations. So you can incorporate the collagenase in petroleum jelly or paraffin.
  • the collagenase is added to the preparations in an amount of about 0.4 to 2.0 units, preferably 0.6 to 1.2 units, per g.
  • Suitable preparations are, for example, ointments, liposomes, powders, lotions and microencapsulations.
  • the wound in the fur can be healed quickly.
  • the preparation is usually applied to the skin one to four times a day.
  • the wound has usually healed already after a treatment of 2 to 5 days with the preparation. However, it is advisable to continue the treatment for a few more days.
  • the following examples illustrate the invention.
  • a preparation of 1 g collagenase (1000 U / g) in 1000 g of a mixture of viscous paraffin and white petroleum jelly (1: 1) was used as the collagenase preparation.
  • a sport horse showed bulging changes under the fur in the area of the restraints. Treatment with antibiotics had had no visible success after 2 weeks. After a week's treatment (3 times a day) with collagenase, the bulge-like changes could be removed. After another week, the treatment was successfully completed.
  • a cow showed signs of inflammation on the udder that could not be removed with antibiotics. After treatment (3 times a day) with collagenase for 3 days, the inflammation had subsided and did not recur.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the use of collagenase for preparing externally applied medicaments for treating wounds on large, hide-covered animals.

Description

Neue Verwendung von CollagenaseNew use of collagenase
Beschreibungdescription
Die vorliegende Erfindung betrifft eine neue Anwendung von Colla¬ genase in der Tiermedizin.The present invention relates to a new application of collagenase in veterinary medicine.
An felltragenden Tieren werden Wunden, die durch Abschürfungen oder Infektionen entstehen, mit Haupflegemitteln oder mit keimtö¬ tenden Substanzen (Antibiotika) behandelt. So werden solche Wun¬ den z.T. mit Ölen behandelt, wobei die geschädigte Hautpartie mit dem Öl bzw. einem ölhaltigen Produkt abgedeckt und vor äußeren Einflüssen geschützt wird. Der eigentliche Heilungsprozeß wird dadurch aber nicht beschleunigt. Auch die Behandlung mit antibio- tikahaltigen Produkten ist recht langwierig und in vielen Fällen erfolglos.On fur-bearing animals, wounds caused by abrasions or infections are treated with main care products or with germicidal substances (antibiotics). Such wounds are partly treated with oils, covering the damaged area of the skin with the oil or an oil-containing product and protecting it from external influences. This does not accelerate the actual healing process. Treatment with antibiotic-containing products is also quite lengthy and in many cases unsuccessful.
Gegenstand der Erfindung ist die Verwendung von Collagenase zur Herstellung von äußerlich anwendbaren Arzneimitteln zur Behand¬ lung von Wunden an feiltragenden Großtieren.The invention relates to the use of collagenase for the production of externally applicable medicaments for the treatment of wounds on large animals carrying files.
Als Collagenase eignet sich beispielsweise diejenige, die aus Clostridia histolyticum gewonnen wird und auch in der Human-Medi- zin verwendet wird. Sie kann aber auch aus anderen Clostridia Bakterien oder Gewebe isoliert werden (Merck Index, Nr. 2477) .A suitable collagenase is, for example, that which is obtained from Clostridia histolyticum and is also used in human medicine. However, it can also be isolated from other Clostridia bacteria or tissues (Merck Index, No. 2477).
Als felltragende Großtiere sind hauptsächlich Rinder und ins¬ besondere Pferde zu nennen.Cattle and especially horses are to be mentioned as large fur-bearing animals.
Als Grundlagen für die Zubereitungen können die für die Haut¬ pflege üblicherweise verwendeten Mischungen verwendet werden. So kann man die Kollagenase in Vaseline oder Paraffin einarbeiten.The mixtures usually used for skin care can be used as the basis for the preparations. So you can incorporate the collagenase in petroleum jelly or paraffin.
Die Collagenase wird in den Zubereitungen in einer Menge von etwa 0,4 bis 2,0 Einheiten, vorzugsweise 0,6 bis 1,2 Einheiten, pro g zugegeben. Als Zubereitungen eignen sich beispielsweise Salben, Liposomen,Pulver, Lotionen und Mikroverkapselungen.The collagenase is added to the preparations in an amount of about 0.4 to 2.0 units, preferably 0.6 to 1.2 units, per g. Suitable preparations are, for example, ointments, liposomes, powders, lotions and microencapsulations.
Mit Hilfe der beschriebenen Zubereitung läßt sich eine rasche Ausheilung der Wunde im Fell erzielen. Die Zubereitung wird in der Regel ein- bis viermal täglich auf die Haut aufgetragen. Be¬ reits nach einer Behandlung von 2 bis 5 Tagen mit der Zubereitung ist die Wunde in der Regel zugeheilt.Es empfiehlt sich jedoch, die Behandlung noch einige Tage fortzusetzen. Die folgenden Beispiele erläutern die Erfindung. Als Collagenase- Zubereitung diente eine Zubereitung von 1 g Collagenase (1000 E/g) in 1000 g einer Mischung aus dickflüssigem Paraffin und weißer Vaseline (1:1) .With the help of the preparation described, the wound in the fur can be healed quickly. The preparation is usually applied to the skin one to four times a day. The wound has usually healed already after a treatment of 2 to 5 days with the preparation. However, it is advisable to continue the treatment for a few more days. The following examples illustrate the invention. A preparation of 1 g collagenase (1000 U / g) in 1000 g of a mixture of viscous paraffin and white petroleum jelly (1: 1) was used as the collagenase preparation.
Beispiel 1example 1
Ein ein Jahr altes Pferd hatte durch Tragen eines Ledergürtels eine Abschürfung, die entzündet war. Eine mehrwöchige Behandlung mit Antibiotka führte zu keiner deutlichen Besserung. Nach vier¬ tägiger Behandlung (2 x täglich) mit Collagenase begann die Wunde abzuheilen. Nach einer weiteren Woche war die Wunde geschlossen.A year-old horse had an abrasion that was inflamed due to wearing a leather belt. Treatment with Antibiotka for several weeks did not improve significantly. After four days of treatment (twice daily) with collagenase, the wound began to heal. After another week the wound was closed.
Beispiel 2Example 2
Ein Sportpferd zeigte beulenartige Veränderungen unter dem Fell im Bereich der Fesseln. Die Behandlung mit Antibiotika hatte nach 2 Wochen zu keinem sichtbaren Erfolg geführt. Nach einer einwö- chigen Behandlung (3 x täglich) mit Collagenase ließen sich die beulenartigen Veränderungen ablösen. Nach einer weiteren Woche war die Behandlung erfolgreich abgeschlossen.A sport horse showed bulging changes under the fur in the area of the restraints. Treatment with antibiotics had had no visible success after 2 weeks. After a week's treatment (3 times a day) with collagenase, the bulge-like changes could be removed. After another week, the treatment was successfully completed.
Beispiel 3Example 3
Eine Kuh zeigte Entzündungserscheinungen am Euter, die sich mit Antibiotika nicht beseitigen ließen. Nach einer Behandlung (3 x täglich) mit Collagenase über 3 Tage war die Entzündung abgeklun¬ gen und trat nicht wieder auf. A cow showed signs of inflammation on the udder that could not be removed with antibiotics. After treatment (3 times a day) with collagenase for 3 days, the inflammation had subsided and did not recur.

Claims

PatentanspruchClaim
Verwendung von Collagenase zur Herstellung von äußerlich anwend- baren Arzneimitteln zur Behandlung von Wunden an feiltragenden Großtieren. Use of collagenase for the manufacture of externally applicable medicinal products for the treatment of wounds in large animals.
PCT/EP1996/002480 1995-06-16 1996-06-07 Novel use of collagenase WO1997000082A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19521829.9 1995-06-16
DE1995121829 DE19521829A1 (en) 1995-06-16 1995-06-16 New use of collagenase

Publications (1)

Publication Number Publication Date
WO1997000082A1 true WO1997000082A1 (en) 1997-01-03

Family

ID=7764468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002480 WO1997000082A1 (en) 1995-06-16 1996-06-07 Novel use of collagenase

Country Status (2)

Country Link
DE (1) DE19521829A1 (en)
WO (1) WO1997000082A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
EP0468411A2 (en) * 1990-07-23 1992-01-29 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija S P.O. A mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
EP0543521A2 (en) * 1991-11-20 1993-05-26 Advance Biofactures Of Curacao N.V. High dosage topical forms of collagenase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
EP0468411A2 (en) * 1990-07-23 1992-01-29 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija S P.O. A mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
EP0543521A2 (en) * 1991-11-20 1993-05-26 Advance Biofactures Of Curacao N.V. High dosage topical forms of collagenase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHVAPIL M ET AL: "DYNAMICS OF THE HEALING OF SKIN WOUNDS IN THE HORSE AS COMPARED WITH THE RAT.", EXP MOL PATHOL 30 (3). 1979. 349-359, XP000605216 *

Also Published As

Publication number Publication date
DE19521829A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
DE69935522T2 (en) COSMETIC OR DERMOPHARMETTIC USE OF PEPTIDES FOR WOUND HEALING, HYDRATIZATION, IMPROVEMENT OF SKIN OVERHEAD IN NATURAL OR ACCELERATED AGING (HELIODERMIA, ENVIRONMENTAL POLLUTION)
DE69127020T2 (en) Milk protein hydrolyzates and compositions for use as hair and skin treatments
DE4393944B4 (en) Use of ecdysteroid in cosmetic or dermatological compsns or culture media - to stimulate differentiation of keratinocytes, e.g. for treating psoriasis or ichthyosis and in prepn of skin grafts
DE3726797A1 (en) MEDICINAL PRODUCTS FOR ORAL CAVES
ATE140918T1 (en) DERIVATIVES IN THE VITAMIN D SERIES WITH MODIFICATIONS IN THE 20 POSITION, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS FOR THIS METHOD, PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES AND THEIR USE FOR THE PRODUCTION OF MEDICINAL PRODUCTS
DE4100975A1 (en) Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth
DE3784695T2 (en) Use of Gramineae extracts as a medicine.
DE1617780B2 (en) Scarring agents
DE69305267T2 (en) Composition for the treatment of mastitis and metritis
EP0366888B1 (en) Pharmaceutical preparation for treating inflammations of the nasal mucous membranes
WO1997000082A1 (en) Novel use of collagenase
DE1768575C3 (en) 0- (5-Indanyl) -m, N-dimethylthionocarbanilate, process for its preparation and pharmaceuticals containing it
Engländer et al. Untersuchungen zur Klärung der Leistungsspezifität verschiedener abnormer Induktoren bei der Embryonalentwicklung der Urodelen
DE2327687A1 (en) ANTISEPTIC MEDIUM
DE69935889T2 (en) Polyphosphoric acid-containing cell growth accelerator and its use
EP1352566B1 (en) Process for the manufacture of a preparation containing active principles from cannabis
DE3143624A1 (en) Cosmetic composition for enhancing and promoting hair growth, and process for the preparation thereof
EP0744177A2 (en) Composition containing at least one essential oil and a provitamin, useful in the prevention and treatment of pressure sores
DE2659462A1 (en) Moist silica hydrogel prodn. for pharmaceutical use - esp. in dental gels for treating parodontal disease
EP0463138B1 (en) Drug for improving the reactions of the ovary and the production of ova and embryos in domestic mammals in connection with biotechnological embryo transfer
DE1922193C3 (en) N-propionyl-e-aminocaproic acid, process for their preparation and medicaments and cosmetic compositions containing them
DE69118796T2 (en) Scarring pharmaceutical compound
DE68901852T2 (en) PRIMYCIN SOLUTIONS.
DE1467791A1 (en) Method of excretion, particularly of fetal organs
EP0311963B1 (en) Therapeutical medium comprising an extract of impatiens capensis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
122 Ep: pct application non-entry in european phase